Olaratumab Alternatives Compared
| Olaratumab | Votrient (pazopanib) | Pazopanib |
|
|---|
| Olaratumab | Votrient (pazopanib) | Pazopanib |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Soft Tissue Sarcoma. Olaratumab may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Soft Tissue Sarcoma, Renal Cell Carcinoma. Votrient may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Soft Tissue Sarcoma, Renal Cell Carcinoma. Pazopanib may also be used for purposes not listed in this medication guide. |
Related suggestions Soft Tissue Sarcoma
|
|||||||||||||||
| More about Olaratumab | More about Votrient (pazopanib) | More about Pazopanib | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Be the first to share your experience with this drug. |
Votrient has an average rating of 8.0 out of 10 from a total of 82 ratings on Drugs.com. 74% of reviewers reported a positive effect, while 9% reported a negative effect. |
Pazopanib has an average rating of 8.0 out of 10 from a total of 92 ratings on Drugs.com. 74% of reviewers reported a positive effect, while 9% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Olaratumab side effects |
View all Votrient side effects |
View all Pazopanib side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
Lower cost generic |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Votrient prices |
View all Pazopanib prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
|
N/A |
N/A |
Votrient | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
576 hours |
30.9 hours |
30.9 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 166 drugs are known to interact with Olaratumab:
|
A total of 708 drugs are known to interact with Votrient:
|
A total of 708 drugs are known to interact with Pazopanib:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
October 19, 2009 |
October 19, 2009 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.